6 Results for "

acute ischemic brain injury

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "acute ischemic brain injury" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-112248A
CAS No.: 1245653-57-9
Purity:  99.76%
HAMI 3379 is a potent and selective CysLT2 receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-126562
CAS No.: 5950-12-9
Purity:  99.31%
Piperlonguminine is a cytochrome P450 (CYP450) inhibitor. Piperlonguminine also inhibits the growth of epimastigotes and intracellular amastigotes of Trypanosoma cruzi, with IC50 values of 53.8 and 33.9 μM, respectively . Piperlonguminine regulates HMGB1/TLR4-NF-κB/MAPK-related inflammatory responses, endothelial protein C receptor (EPCR) shedding, melanogenesis, glycolipid metabolism, ischemic brain injury and tumor growth. Piperlonguminine can be used in research on hyperlipidemia, sepsis, Chagas disease, ischemic stroke, sarcoma and severe acute pancreatitis-associated lung injury .
loading...
    loading...
Cat. No.: HY-162596
CAS No.: 1973494-16-4
Synonyms: BA-1049 free base
Target:  

ROCK

Research Areas:  

Neurological Disease

NRL-1049 (BA-1049 (free base)) is an orally available and selective ROCK2 inhibitor with IC50 values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations .
loading...
    loading...
Cat. No.: HY-116444
CAS No.: 183509-23-1
Target:  

Cytochrome P450

Research Areas:  

Neurological Disease

16(S)-HETE is an endogenous inhibitor of neutrophil activity and can be used in the study of acute ischemic brain injury .
loading...
    loading...
Cat. No.: HY-126562R
CAS No.: 5950-12-9
Piperlonguminine (Standard) is the analytical standard of Piperlonguminine (HY-126562). This product is intended for research and analytical applications. Piperlonguminine is a cytochrome P450 (CYP450) inhibitor. Piperlonguminine also inhibits the growth of epimastigotes and intracellular amastigotes of Trypanosoma cruzi, with IC50 values of 53.8 and 33.9 μM, respectively . Piperlonguminine regulates HMGB1/TLR4-NF-κB/MAPK-related inflammatory responses, endothelial protein C receptor (EPCR) shedding, melanogenesis, glycolipid metabolism, ischemic brain injury and tumor growth. Piperlonguminine can be used in research on hyperlipidemia, sepsis, Chagas disease, ischemic stroke, sarcoma and severe acute pancreatitis-associated lung injury .
loading...
    loading...
Cat. No.: HY-162596A
CAS No.: 863638-93-1
Synonyms: (Rac)-BA-1049
Target:  

ROCK

Research Areas:  

Neurological Disease

(Rac)-NRL-1049 is the racemic mixture of NRL-1049 (BA-1049 (free base)) (HY-162596). NRL-1049 is an orally available and selective ROCK2 inhibitor with IC50 values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations .
loading...
    loading...